A detailed history of Private Capital Group, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Private Capital Group, LLC holds 206 shares of RARE stock, worth $9,731. This represents 0.01% of its overall portfolio holdings.

Number of Shares
206
Previous 206 -0.0%
Holding current value
$9,731
Previous $15,000 20.0%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 21, 2022

SELL
$62.2 - $84.4 $124 - $168
-2 Reduced 0.96%
206 $15,000
Q4 2021

Jan 24, 2022

BUY
$73.71 - $87.86 $147 - $175
2 Added 0.97%
208 $18,000
Q3 2021

Oct 13, 2021

SELL
$77.92 - $102.4 $155 - $204
-2 Reduced 0.96%
206 $19,000
Q2 2021

Jul 26, 2021

SELL
$92.19 - $115.71 $645 - $809
-7 Reduced 3.26%
208 $20,000
Q1 2021

Apr 12, 2021

SELL
$106.9 - $167.73 $34,742 - $54,512
-325 Reduced 60.19%
215 $24,000
Q4 2020

Jan 26, 2021

SELL
$84.4 - $177.39 $84 - $177
-1 Reduced 0.18%
540 $75,000
Q3 2020

Nov 12, 2020

BUY
$72.98 - $90.0 $948 - $1,170
13 Added 2.46%
541 $44,000
Q2 2020

Aug 13, 2020

BUY
$46.91 - $78.22 $938 - $1,564
20 Added 3.94%
528 $41,000
Q1 2020

May 07, 2020

BUY
$33.8 - $62.9 $5,881 - $10,944
174 Added 52.1%
508 $23,000
Q4 2019

Feb 14, 2020

BUY
$36.08 - $45.83 $10,824 - $13,749
300 Added 882.35%
334 $14,000
Q1 2018

May 16, 2018

SELL
$44.33 - $58.52 $64,987 - $85,790
-1,466 Reduced 97.73%
34 $2,000
Q4 2017

May 18, 2018

BUY
$43.54 - $57.32 $59,127 - $77,840
1,358 Added 956.34%
1,500 $2,000
Q4 2017

Mar 07, 2018

BUY
$43.54 - $57.32 $6,182 - $8,139
142
142 $2,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.31B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Private Capital Group, LLC Portfolio

Follow Private Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Private Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Private Capital Group, LLC with notifications on news.